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Background: There are no criteria for selecting single- or dual-chamber implantable cardioverter deﬁ-
brillators (ICDs) in patients without a pacing indication. Recent reports showed no beneﬁt of the dual-
chamber system despite its preference in the United States. As data on ICD selection and respective
outcomes in Japanese patients are scarce, we investigated trends regarding single- and dual-chamber ICD
usage in Japan.
Methods: Data from a total of 205 ICD recipients with structural heart disease (median age, 63 years) in
two Japanese university hospitals were reviewed. Patients with bradycardia with a pacing indication and
permanent atrial ﬁbrillation at implantation were excluded.
Results: Single- and dual-chamber ICDs were implanted in 36 (18%) and 169 (82%) patients, respectively.
Non-ischemic cardiomyopathy dominated both groups. Seventeen dual-chamber patients developed
atrial pacing-dependency over 4.5 years, and it developed immediately after implantation in 14.
Although preoperative testing showed no sign of bradycardia in these patients, their pacing rate was set
higher than it was in patients who were pacing-independent (61 vs. 46 paces per min, po0.01). Two
single-chamber patients (5%) underwent atrial lead insertion.
While inappropriate shock equally occurred in both groups (7 vs. 21 patients, single- vs. dual-
chamber, P¼0.285), device-related infection occurred only in dual-chamber patients (0 vs. 9 patients,
P¼0.155). No differences in death or heart failure hospitalization were observed between groups.
Conclusions: Dual-chamber ICDs were four-fold more common in Japanese patients without a pacing
indication. No beneﬁt over single-chamber ICD was observed. Newly developed atrial pacing-
dependency seemed to be limited and could have been overestimated due to higher pacing rate set-
tings in dual-chamber patients.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.blished by Elsevier B.V. All rights
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There have been no clear established criteria for the selection of
single- or dual-chamber implantable cardioverter deﬁbrillators (ICDs)
in patients without a pacing indication. In the United States, dual-
chamber ICDs are predominantly used [1–3], but the reason for this
trend is unclear. Potential beneﬁts of dual-chamber ICD systems, such
as superior supraventricular tachycardia (SVT) discrimination with
atrial sensing [4,5] or physiological pacing for potential future bra-
dycardia development [6], could encourage the physicians’ pre-
ference. Recent studies, however, demonstrated that not only didreserved.
A. Ueda et al. / Journal of Arrhythmia 32 (2016) 89–9490dual-chamber ICDs have no additional beneﬁt over single-chamber
ICDs but that they also resulted in a higher incidence of lead mal-
functions or other adverse events [3]. These data shed light on the
importance of careful consideration when selecting dual-chamber
ICDs in patients without a pacing indication.
The proportion of non-ischemic cardiomyopathy (NICM) in the
Japanese ICD cohort is higher than that of ischemic cardiomyopathy
(ICM) [7]. The different background of these patients might affect
physicians’ decisions on ICD selection and lead to different clinical
courses. As data on dual- or single-chamber ICD selection and
respective outcomes in Japan are scarce, the aim of this study was to
understand the Japanese trend in ICD selection and clinical outcomes.2. Materials and methods
2.1. Patient selection
Two hundred seventy-seven consecutive patients (median age 68
years; interquartile range [Q1–3], 53–74 years; 69 women) who
underwent ICD implantation and were followed from November 1994
to December 2013 in two Japanese university hospitals (Kyorin
University Hospital, Tokyo, and the University Hospital at the University
of Occupational and Environmental Health, Kitakyushu, Japan) were
reviewed. Exclusion criteria were: (1) idiopathic ventricular tachycardia
(VT)/ﬁbrillation (VF), including Brugada syndrome and long QT syn-
drome; (2) known sinus node or atrioventricular node dysfunctionwith
a pacing indication; and (3) permanent atrial ﬁbrillation (AF) at the time
of implantation. The remaining patients were then categorized into two
groups according to the ICD type (i.e., single-chamber ICD and dual-
chamber ICD). Decisions regarding ICD implantation were made
according to the most recent Japanese guidelines for cardiac-
implantable devices at the time of implantation [8–10]. The types of
ICD and the settings of the pacing and antitachycardia therapy were
selected based on the operators’ decisions. Although neither university
hospital had standard criteria for ICD type selection, operators referred
to the patients’ information on the use of negative chronotropic med-
ications and results of preoperative testing. Every researchers involved
in this study acted inconformity with the Declaration of Helsinki
(adopted by the 18th WMA General Assembly, Helsinki, Finland).
2.2. Preoperative testing
Data from preoperative transthoracic echocardiography and
24-hour ambulatory monitoring within 6 months prior to
implantation were evaluated.
2.3. Follow-up
All patients were followed in the outpatient device clinic every
3–4 months, and the devices were interrogated at each clinic visit
or remotely. When bradycardia was observed, the pacing mode or
a lower rate adjustment was considered in addition to the dis-
continuation of medication if necessary. A pacing rate change was
attempted in patients for whom the tachyarrhythmia was believed
to have been triggered by bradycardia. Additionally, the pacing
mode was changed in case of a lead malfunction, such as an
increased pacing threshold or progression of AF from a paroxysmal
to persistent form. When the pacing ratio was 80% or more in the
atria and/or in the ventricle, we deﬁned it as an atrial or ven-
tricular pacing dependency. Decisions regarding additional lead
insertion or an upgrade to a cardiac resynchronization therapy
deﬁbrillator (CRTD) were made by the electrophysiological team
after a detailed discussion. The patients were advised to visit the
hospital when they experienced any shock delivery, palpitations,
or other issues, such as skin redness or erosion.2.4. Data collection
Data collection was closed by the end of December 2013. The
pacing and therapy histories were collected from medical records
at the outpatient device clinic. The follow-up period was deﬁned
as the period from the day of the initial ICD implantation to the
last day that the physician contacted the patient before December
2013. When a patient underwent a CRTD upgrade, data collection
was closed on the day of the upgrade.
2.5. Statistical analysis
Normally distributed continuous variables were expressed as
the mean and standard deviation. Non-normally distributed vari-
ables were expressed as the median and ﬁrst to third interquartile
range (Q1–3). Categorical data were expressed as absolute num-
bers and/or percentages. Comparisons between the two groups
were assessed by the two-tailed t-test or Mann–Whitney U-test
according to a variable distribution. A Chi-squared test or Fisher’s
exact test was performed for the comparisons of categorical data.
Statistical signiﬁcance was set at po0.05. All analyses were per-
formed with SPSS statistical software (SPSS Inc., Chicago, IL, USA).3. Results
3.1. Patient demographics
Among the 277 ICD patients who underwent initial implantation
at one of two hospitals, 72 were excluded from the study for the
following reasons: idiopathic VT or VF in 39 patients (26 with a
single-chamber ICD), permanent AF in 26 patients, sick sinus syn-
drome in ﬁve patients, and atrioventricular block in two patients.
Three of the excluded 72 patients had previously received a pace-
maker and then underwent an ICD upgrade. Therefore, the remaining
205 patients (median age, 63 years; Q1–3, 56–75 years; 59 women)
were enrolled in the study. Single- and dual-chamber ICDs were
selected in 36 (18%) and 169 (82%) patients, respectively (Fig. 1). There
were no signiﬁcant differences between the two groups with regard
to age, sex, and proportion of NICM (Table 1). Patients with a primary
prevention indication tended to receive a dual-chamber system (17%
in the single- vs. 33% in the dual-chamber group, P¼0.048). Patients
in the dual-chamber group were more frequently taking class III
antiarrhythmic drugs (mostly amiodarone), although it was not sta-
tistically signiﬁcant (31% and 48%, P¼0.053). Beta blockers were more
frequently used in the dual-chamber group (36% and 58%, P¼0.014).
Table 1 shows the results of preoperative testing. Echocardio-
graphy and 24-hour ambulatory monitoring data were available in
168 (82%) and 108 (53%) patients, respectively. While left ven-
tricular systolic function was lower in the dual-chamber group
(left ventricular ejection fraction, 54% vs. 46%; P¼0.034), the total
heart beats per day and maximum, mean and minimum heart
rates were similar between the two groups. There was no evidence
of bradycardia on 24-hour ambulatory monitoring in either group.
3.2. Follow-up
The mean duration of follow-up was 56 months (Table 2). A
total of 65 (32%) ICD generators were exchanged, and three
patients (1.4%, all in the dual-chamber group) were upgraded to
CRTD (one patient at the time of the generator exchange and two
patients due to worsening heart failure). Apart from the left ven-
tricular lead insertion for CRTD, a total of 13 leads were added in
12 patients. Nine patients (two in the single- and seven in the
dual-chamber group) had ventricular shock leads re-implanted
due to lead malfunction (four for lead fractures and ﬁve for
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ical, Inc., Sylmar, CA) and three were Sprint Fidelis leads (Med-
tronic, Inc., Minneapolis, MN). One patient underwent lead
implantation due to ventricular under-sensing. One atrial lead was
re-implanted because of a high pacing threshold. Two atrial leads
were newly implanted at the time of the generator exchange in
patients who initially received single-chamber ICDs.
3.3. Device-related infections, other device-related adverse events,
and death or heart failure hospitalizations
No patients in the single-chamber group experienced any device-
related infections. In contrast, nine patients in the dual-chamberTable 1
Demographic data.
Total (n¼205)
Age at implantation, median (Q1–3) 63 (56–75)
Female sex, n (%) 59 (29)
Non-ischemic cardiomyopathy, n (%) 117 (57)
Primary prevention, n (%) 62 (30)
Preoperative SVT Documentation, n (%) 35 (17)
Height (m), mean7SD 1.6270.10
Weight (kg), mean7SD 58.9712.0
BSA (m2), mean7SD 1.670.2
BMI (kg/m2), mean7SD 22.573.4
Medication at the time of implantation, n (%)
Class I antiarrhythmic drug 14 (7)
Class III antiarrhythmic drug 92 (45)
Calcium channel blocker 42 (20)
Beta blocker 111 (54)
TTE at implantation, mean7SD
LVEF (%) 47717
LVDd (mm) 53710
LVDs (mm) 53710
LAD (mm) 39713
24-hour ambulatory ECG monitoring, mean7SD
Total heart beat (/day) 96,350718,119
Minimum HR (bpm) 54716
Average HR (bpm) 67713
Maximum HR (bpm) 99722
BMI, body mass index; BSA, body surface area; ECG, electrocardiogram; HR, heart rate
ventricular systolic dimension; LVEF, left ventricular ejection fraction; Q1–3, ﬁrst to third
transthoracic echocardiography.
n Statistically signiﬁcant.
Fig. 1. Selection of the study participants. After excluding patients with idiopathic
ventricular ﬁbrillation/tachycardia, permanent atrial ﬁbrillation, and sinus node or
atrioventricular node dysfunction, a total of 205 patients were enrolled in the
study. AV, atrioventricular; ICD, implantable cardioverter deﬁbrillator; SSS, sick
sinus syndrome; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.group (5%) experienced device-related infections requiring long-term
antimicrobial therapy, although this difference was not statistically
signiﬁcant (P¼0.155). Four of nine patients required lead extraction.
All body habitus markers, except for body mass index (BMI), were not
signiﬁcantly different between patients with infections and those
without infections (BMI, 19.9 kg/m2 in patients with infection vs.
22.3 kg/m2 in patients without infection; P¼0.033, not shown in the
Tables). Death or heart failure admissions were similarly observed in
the two groups.
3.4. Antitachycardia therapy history
The incidence of tachyarrhythmia therapy is shown in Table 2.
Antitachycardia therapy was initially programmed for the VF zone
only in 51 patients and for both the VT and VF zones in 154
patients. The proportions of the zone settings were similar
between the two groups (VF zone only, 36% in the single-chamber
group vs. 22% in the dual-chamber group; P¼0.086). Inappropriate
shocks due to SVT or sinus tachycardia were similarly observed in
patients with single- and dual-chamber group patients. The causes
of inappropriate shocks were AF or other SVT (n¼5) and sinus
tachycardia (n¼2) in the single-chamber group, and AF or SVT
(n¼17), sinus tachycardia (n¼2), and noise oversensing (n¼2) in
the dual-chamber group. The antitachycardia zone settings were
not associated with the incidence of inappropriate shocks
(P¼0.167, not shown in the Tables).
3.5. Initial and subsequent pacing settings
The initial pacing mode in the single-chamber group was VVI,
and the pacing rate was set to 40–60 paces per minute (ppm). In
the dual-chamber group, 151 patients (89%) had a DDD or DDI
mode, including DDD with an algorithm that minimized right
ventricular pacing (eight patients), and the lower pacing rateSingle-chamber n¼36 Dual-chamber n¼169 Difference
61 (51–73) 68 (58–75) P¼0.099
11 (31) 48 (28) P¼0.796
19 (53) 98 (58) P¼0.566
6 (17) 56 (33) P¼0.048n
3 (8) 32 (19) P¼0.125
1.6370.10 1.6270.19 P¼0.771
58.7710.6 59.4712.3 P¼0.787
1.670.2 1.670.2 P¼0.697
22.172.9 22.673.5 P¼0.483
2 (6) 12 (7) P¼0.736
11 (31) 81 (48) P¼0.053
9 (25) 33 (21) P¼0.462
13 (36) 98 (58) P¼0.014n
54715 46718 P¼0.034n
5179 53710 P¼0.467
5179 40713 P¼0.193
3979 4078 P¼0.085
94,491712,009 96,826719,409 P¼0.601
5077 55717 P¼0.107
6679 68714 P¼0.455
99718 99723 P¼0.981
; LAD, left atrial dimension; LVDd, left ventricular diastolic dimension; LVDs, left
interquartile range; SD, standard deviation; SVT, supraventricular tachycardia; TTE,
Table 2
Follow-up data.
Total (n¼205) Single-chamber (n¼36) Dual-chamber (n¼169) Difference
Follow-up period (months) 56735 64739 54734 P¼0.130
Setting changes
Additional lead insertion, n (%) 13 (6) 4 (11) 9 (5) P¼0.147
Pacing setting change, n (%) 29 (14) 3 (8) 26 (15) P¼0.270
Time from implant to setting change (months), median (Q1–3) 37 (21–80) 89 (89–104) 35 (20–74) P¼0.009n
Adverse events
Lead malfunction, n (%) 14 (7) 2 (6) 12 (7) P¼0.739
Infection, n (%) 9 (4) 0 (0) 9 (5) P¼0.155
Skin complications, n (%) 14 (7) 4 (11) 10 (6) P¼0.267
Death and hospitalization
Death (all causes), n (%) 47 (23) 5 (14) 42 (26) P¼0.155
Death d/t cardiac cause, n (%) 12 (6) 1 (3) 11 (7) P¼0.613
Admission d/t heart failure, n (%) 33 (16) 5 (14) 28 (17) P¼0.587
Therapy history
Initial antitachycardia therapy zone, n (%) VF only 51 (25) VF only 13 (36) VF only 38 (22) P¼0.086
VT 154 (75) VT 23 (64) VT 131 (78)
Duration from implant to inappropriate shocks (months), median (Q1–3) 24 (9–61) 56 (13–75) 23 (7–44) P¼0.220
Appropriate shock, n (%) 39 (19) 8 (22) 31 (18) P¼0.625
Appropriate ATP, n (%) 44 (21) 5 (14) 39 (23) P¼0.206
Inappropriate shocks, n (%) 28 (14) 7 (19) 21 (12) P¼0.285
Newly diagnosed SVT, n (%) 50 (24) 8 (22) 42 (25) P¼0.996
ATP, anti-tachycardia pacing; d/t, due to; Q1–3, ﬁrst to third interquartile range; SVT, supraventricular tachycardia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
n Statistically signiﬁcant.
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had a VVI mode with a pacing rate of 40 or 50 ppm.
The pacing mode or rate was changed in three patients in the
single-chamber group (8%) and 26 in the dual-chamber group
(15%) during the follow-up period (P¼0.270). Among the three
patients in the single-chamber group, two underwent an addi-
tional atrial lead insertion and the pacing mode was changed to
DDD at the time of the generator exchange: one patient with
obstructive hypertrophic cardiomyopathy underwent a single- to
dual-ICD upgrade 90 months after the initial implantation for
short AV interval pacing to reduce the outﬂow pressure gradient of
the left ventricle, and the other patient with paroxysmal AF and an
old myocardial infarction had an atrial lead implanted for the
overdrive pacing. In the dual-chamber group, the DDD mode was
changed to VVI in one patient because of a high atrial pacing
threshold. Seven patients developed paroxysmal or persistent AF,
and the DDD mode was changed to DDI or VVI. Two patients had
the pacing rate decreased for unknown reasons. Although the
pacing rate was increased to improve bradycardia or to inhibit
premature beats triggering SVT or ventricular arrhythmias in 16
patients, 13 of them were still pacing-independent at the time of
study closure.
The interval from implantation to setting change was 89 (Q1–3;
89–104) months in the single-chamber group and 35 (Q1–3; 20–
74) months in the dual-chamber group, respectively, indicating
that setting changes were attempted at a signiﬁcantly earlier stage
in dual-chamber patients (P¼0.009).
3.6. Atrial and ventricular pacing dependency
Information on the atrial pacing ratio at the time of implanta-
tion and the follow-up closure was available in 34 patients (94%) in
the single-chamber group and 161 in the dual-chamber
group (95%).
Seventeen patients in the dual-chamber group (11%) had
developed atrial-pacing dependency (atrial-pacing ratio Z80%) by
the end of follow-up, and 13 of them (76%) had developed itimmediately after implantation. A comparison between the
patients who were atrial-pacing dependent or independent is
shown in Table 3. Patients in both categories were demo-
graphically similar. Although the 24-hour ambulatory monitoring
data were similar without any sign of bradycardia, the initial
pacing rate was programmed signiﬁcantly higher in patients who
were pacing-dependent (61 ppm vs. 49 ppm, po0.001). Pro-
gressive bradycardia requiring atrial pacing in the mid-course of
the follow-up was observed only in four patients in the dual-
chamber group (2%).
Ventricular pacing dependency (ventricular pacing ratio
Z80%) by the end of follow-up was observed in 18 patients (7% of
all patients). All but one patient were in the dual-chamber group.4. Discussion
4.1. Main ﬁndings
This observational study revealed that: (1) dual-chamber ICDs
accounted for more than 80% of the total ICD implantations in two
Japanese university hospitals; (2) the incidence of inappropriate
shocks and other adverse events were similarly low in the single-
and dual-chamber ICD groups; (3) 11% of the dual-chamber ICD
recipients developed an earlier atrial-pacing dependency with a
higher pacing rate; (4) newly developed pacing dependency
seemed to be limited in both groups; and (5) no differences were
observed in the incidence of death or heart failure hospitalization
in either group.
4.2. Trends for dual- and single-chamber ICD selection
Dual-chamber ICDs were selected four-fold more frequently as
compared to single-chamber ICDs in the two university hospitals
in Japan. Although similar trends were reported in recent studies
from the United States that revealed that dual-chamber ICDs were
used 1.5–2 times more frequently [1–3], the preference for dual-
Table 3
Dependent/independent atrial pacing in the dual-chamber group.
Ap-dependent
(n¼17)
Ap-independent
(n¼144)
Differences
Age at implantation,
median (Q1–3)
69 (64–77) 66 (56–75) P¼0.163
Follow-up period
(months), mean7SD
53741 56733 P¼0.725
Female sex, n (%) 7 (41) 40 (28) P¼0.250
Non-ischemic heart
diseases, n (%)
11 (65) 83 (58) P¼0.576
Primary prevention, n
(%)
5 (29) 47 (33) P¼0.774
Target only VF, n (%) 3 (18) 31 (22) P¼0.711
Preoperative SVT doc-
umentation, n (%)
5 (29) 27 (18) P¼0.298
Medication at the time of implantation, n (%)
Class I antiarrhythmic
drug
2 (13) 8 (6) P¼0.294
Class III antiar-
rhythmic drug
12 (75) 71 (49) P¼0.051
Calcium channel
blocker
5 (31) 27 (19) P¼0262
Beta blocker 8 (50) 85 (61) P¼0.408
24-hours ambulatory ECG monitoring, mean7SD
Total heart beat 96,986721,885 98,080718,776 P¼0.893
Minimum HR (bpm) 58714 56717 P¼0.790
Average HR (bpm) 67715 69713 P¼0.812
Maximum HR (bpm) 84716 99723 P¼0.172
Pacing setting
Initial pacing rate
(ppm), mean7SD
6179 4778 Po0.001n
Pacing setting
change, n (%)
4 21 P¼0.335
Newly diagnosed SVT,
n (%)
4 36 P¼0.833
ECG, electrocardiography; HR, heart rate; Q1–3, ﬁrst to third interquartile range;
SD, standard deviation; SVT, supraventricular tachycardia; VF, ventricular
ﬁbrillation.
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There were several demographic differences between the previous
studies and our study. While previous cohorts received ICDs pri-
marily for primary prevention, 70% of our cohort received ICDs for
secondary prevention. Additionally, while the proportions of NICM
in the previous studies were at most 30% [1,3], more than 50% of
the patients in our study had NICM. These differences are, how-
ever, unable to explain the reason for the selection of dual-
chamber ICDs. In our cohort, we intentionally excluded patients
with pacing dependency at the time of implantation, as previous
studies had shown that approximately 20–40% of patients with
dual-chamber ICDs were pacing-dependent [1]. The extent of the
preference for a dual-chamber system in Japan far exceeded our
expectations.
4.3. Incidence of inappropriate shocks and adverse events
Inappropriate therapy was experienced by 14% of the total
cohort during 4.5 years of follow-up (2.9%/yr), which was com-
parable to that reported in previous studies [11,12]. Although
better SVT discrimination is expected from dual-chamber ICDs,
whether this is true remains controversial [4,5,12–14]. A recent
report from Denmark demonstrated a higher risk of inappropriate
therapy associated with dual-chamber ICDs [14]. Conﬂicting
results among the previous studies may be attributed to the dif-
ferent endpoints, namely inappropriate detection or therapies and
different programming. Leenhaldt et al. reported that ﬁne-tuning
the device programming, such as a higher rate setting of the VTzone, could have prevented half of the inappropriate therapies that
occurred in 11% of their cohort during a mean 22-month follow-up
period [15]. Friedman et al. also demonstrated a low incidence of
inappropriate shocks (2% in a year) not only in patients with dual-
chamber ICDs but also in those with single-chamber ICDs after
optimal programming [16]. These recent reports suggest that
individualized optimal programming is essential, regardless of the
ICD type. As inappropriate shocks are experienced at various times
during follow-up, updating the antitachycardia therapy program-
ming might be useful for preventing future inappropriate thera-
pies. Recently, a new type of ICD ventricular lead with a ﬂoating
atrial sensing bipole has been launched. This lead might offer good
sensitivity and speciﬁcity for SVT discrimination with no addi-
tional implantation time [17].
In this study, device-related infections were observed only in
patients with dual-chamber ICDs, in agreement with previous
studies [18,19]. Although such a tendency was not observed in
recent studies with large numbers of patients [1,3], this difference
might be accounted for by the low incidence of infections (0.02–
0.6%) with a very short follow-up period (o90 days).
Overall, mortality, hospital admissions, and incidence of
adverse events occurred at similar rates in the two groups.
Almendral et al. reported that dual-chamber ICDs were associated
with fewer clinically signiﬁcant adverse events, including all-cause
mortality, invasive interventions, hospitalization for cardiovascular
causes, inappropriate shocks, and sustained symptomatic atrial
tachycardia [13]. In contrast, others reported worse clinical out-
comes in dual-chamber ICD patients [1,3]. Our study was not
designed to determine the superiority of dual-chamber ICDs or the
non-inferiority of single-chamber ICDs, and therefore we cannot
draw any such conclusions. At least, no clear advantages of dual-
chamber ICDs were observed.
4.4. Additional lead insertion and/or pacing setting changes
Among the 36 patients who received a single-chamber ICD,
only two patients (6%) were upgraded to a dual-chamber ICD
during the follow-up period, and one patient was still pacing-
independent even after the upgrade. Among the 169 dual-
chamber ICD recipients, only 11% had developed atrial-pacing
dependency. These results seem to suggest that the necessity of
an atrial lead for future atrial pacing is very limited in NICM-
dominant Japanese ICD patients. Furthermore, the majority of the
atrial-pacing dependency that developed shortly after the
implantation was due to the higher pacing rate setting. It is pos-
sible that these patients became atrial-pacing dependent due to
the unnecessarily high pacing rate setting.
In 1997, Anderson et al. reported that atrial pacing reduced the
incidence of AF in the setting of sick sinus syndrome [20]. This
idea, to some extent, could motivate physicians to set a high atrial
pacing rate. Subsequent studies, including the DAVID-II trial,
however, failed to demonstrate any superiority of atrial pacing
with regard to AF prevention in patients with a low ejection
fraction without bradycardia [21,22]. In this study, the incidence of
newly developed AF was documented equally in the atrial-pacing
dependent and independent patients, in agreement with those
studies, suggesting that atrial pacing failed to prevent AF
effectively.
Pacing mode and rate changes were attempted at an earlier
stage in the dual-chamber group as compared to in the single-
chamber group. This difference may simply be due to the pro-
gramming ﬂexibility that the dual-chamber system provides. Most
of the reprogramming was aimed at increasing the atrial-pacing
ratio in the dual-chamber group; however, the reprogramming
might have been unnecessary because most patients were still
pacing-independent after the change.
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incidence of adverse events, a limited number of patients who
truly required atrial pacing, and a limited impact of pacing
reprogramming might suggest that the dual-chamber ICD system
has been overused. Careful consideration seems to be necessary
for future ICD implantation.
4.5. Limitations
The number of patients in this study was limited. We expect
that future analyses using the Japanese registry would be
taken place.
Additionally, because of the nature of this observational study,
the selection of the ICD type, pacing mode, lower rate settings, and
timing/reasons for setting changes were entirely dependent on the
physicians’ decisions and therefore could be biased. In most cases,
the reasons for the decisions were unclear.
We analyzed data from a limited number of preoperative tests.
More intensive testing, such as 24-hour ambulatory monitoring or
exercise testing, which potentially uncovers chronotropic incom-
petence, could predict the future development of symptomatic
bradycardia.5. Conclusion
Although dual-chamber ICDs were selected four-fold more
frequently in NICM-dominant Japanese ICD cohort that initially
had no bradycardia, our study failed to demonstrate a beneﬁt for
dual-chamber ICDs over single-chamber ICDs in terms of inap-
propriate shock reduction and incidence of device-related adverse
events. Death or heart failure hospitalization was also equally
observed in both the single- and dual-chamber groups. Newly
developed atrial-pacing dependency seemed to be limited and
could have been overestimated due to the unnecessarily higher
pacing rate settings in some patients in the dual-chamber group.
Single-chamber ICD seems to be sufﬁcient in most patients.
Careful consideration when selecting the type of ICD is required
for future implantation.Conﬂict of interest
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